Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) AI Stock Analysis

• Market Cap: HK$1.50B
• Dividend Yield: N/A
• Average Volume (3M): 60.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.12
• Revenue Growth: 17.45%
• EPS Growth: 85.71%
• Country: HK
• Employees: 344
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): -0.39
• Shares Outstanding: 31,565,804
• 10 Day Avg. Volume: 72,755
• 30 Day Avg. Volume: 60,475
• PEG Ratio: 0.59
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: HK$39.00 ▲(3.86%Upside)

The stock score is primarily influenced by strong technical momentum and a robust balance sheet. However, it is significantly impacted by negative valuation metrics and ongoing financial losses, which present substantial risks to long-term profitability.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) is a prominent player in the medical technology sector, specializing in the development and provision of advanced cardiac care solutions. The company's core offerings include innovative medical devices and equipment designed to enhance the diagnosis, treatment, and management of cardiovascular diseases. Leveraging cutting-edge technology, Shanghai Heartcare aims to improve patient outcomes and support healthcare professionals in delivering effective cardiac care.

How the Company Makes Money

Shanghai Heartcare Medical Technology Corp. Ltd. generates revenue primarily through the sale of its medical devices and equipment tailored for cardiovascular care. The company's revenue streams include direct sales to hospitals and healthcare facilities, partnerships with distributors, and collaborations with medical institutions for research and development. Additionally, Shanghai Heartcare might engage in strategic partnerships or licensing agreements to expand its market presence and leverage synergies with other healthcare organizations. The company's earnings are influenced by the demand for cardiovascular solutions, the adoption of its technology in clinical settings, and its ability to innovate and maintain a competitive edge in the medical technology industry.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview

Summary

The company shows strong revenue growth and a stable balance sheet with low leverage and high liquidity. However, it faces profitability challenges with consistent net losses and negative cash flow, which require better profitability and cash management strategies.

Income Statement

The company has shown a positive revenue growth trajectory with a significant increase in total revenue over the years. Gross profit margin is healthy, but the net profit margin remains negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins are also negative, showing operational inefficiencies.

Balance Sheet

The balance sheet is strong with a high equity ratio and low debt-to-equity ratio, indicating financial stability and low leverage. However, the company has been experiencing net losses, affecting its return on equity negatively. High cash reserves provide a strong liquidity position.

Cash Flow

The company has faced challenges in generating positive operating cash flow, with negative free cash flow indicating difficulties in covering capital expenditures. The absence of positive cash flow metrics suggests a need for better cash management and operational efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	277.90M	232.34M	183.03M	90.09M	14.56M
Gross Profit	181.72M	163.76M	124.33M	54.95M	7.09M
EBITDA	21.87M	-68.50M	-167.31M	-183.34M	-206.19M
Net Income	-13.62M	-94.01M	-200.38M	-195.82M	-216.08M
Balance Sheet
Total Assets	1.21B	1.20B	1.31B	1.50B	773.63M
Cash, Cash Equivalents and Short-Term Investments	713.72M	721.14M	870.12M	1.22B	632.42M
Total Debt	35.75M	36.38M	50.69M	41.94M	24.69M
Total Liabilities	144.00M	125.60M	147.08M	132.10M	82.60M
Stockholders Equity	1.06B	1.08B	1.17B	1.37B	681.37M
Cash Flow
Free Cash Flow	-8.39M	-137.72M	-304.01M	-260.33M	-90.42M
Operating Cash Flow	-3.23M	-88.41M	-266.77M	-205.85M	-74.81M
Investing Cash Flow	10.80M	-125.45M	44.84M	-161.10M	-4.53M
Financing Cash Flow	-12.38M	-21.48M	-24.75M	821.25M	686.22M

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Positive. The current price of 37.55 is above the 20-day moving average (MA) of 33.47, above the 50-day MA of 30.11, and above the 200-day MA of 24.97, indicating a bullish trend. The MACD of 2.60 indicates Negative momentum. The RSI at 69.35 is Neutral, neither overbought nor oversold. The STOCH value of 59.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6609.

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1302	72 Outperform	HK$8.59B	37.25	6.49%	―	0.87%	-18.05%
6609	60 Neutral	HK$1.50B	―	-1.28%	―	17.45%	85.71%
Sector *	60 Neutral	HK$15.14B	5.56	-7.43%	4.30%	11.60%	-21.06%
9996	51 Neutral	€4.27B	―	-10.43%	―	36.76%	42.89%
2500	50 Neutral	HK$1.16B	―	-27.82%	―	-6.12%	0.43%
2160	47 Neutral	HK$2.12B	―	-2.19%	―	5.32%	89.43%

Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events

Shanghai HeartCare Successfully Concludes 2024 AGM and EGM

Shanghai HeartCare Medical Technology Corp. Ltd. successfully held its 2024 Annual General Meeting (AGM) and Extraordinary General Meeting (EGM) on May 26, 2025, where all proposed resolutions were passed by poll. The meetings were conducted in compliance with the Company Law of the PRC and the Articles of Association, with significant shareholder participation, indicating robust governance and stakeholder engagement.

The most recent analyst rating on (HK:6609) stock is a Buy with a HK$25.60 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.

Shanghai Heartcare Announces EGM to Discuss 2025 H Share Incentive Scheme

Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.

Shanghai HeartCare Proposes 2025 H Share Incentive Scheme

Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.

Shanghai HeartCare Announces H Share Register Closure for EGM

Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from April 26, 2025, to May 26, 2025, to facilitate its upcoming extraordinary general meeting (EGM) scheduled for May 26, 2025. This closure is aimed at determining the list of shareholders eligible to attend and vote at the EGM, which follows the annual general meeting on the same day. The move is significant for stakeholders as it outlines the procedural steps for shareholder participation and voting, ensuring transparency and orderly conduct of corporate governance.

Shanghai Heartcare Announces 2024 AGM with Key Resolutions

Shanghai Heartcare Medical Technology Corp. Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for May 26, 2025. During the AGM, the company will consider and approve various resolutions, including the work reports of the board and supervisory committee, profit distribution plan, audited financial statements, and the re-appointment of auditors. Additionally, a special resolution will be discussed to authorize the issuance of additional shares, granting the board a general mandate to manage such issuances. These resolutions are pivotal for the company’s strategic planning and financial management, potentially impacting its market position and shareholder value.